WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H562103
CAS#: 2123489-30-3
Description: WNK-IN-11 is a potent, selective and orally active inhibitor of WNK1 kinase.
Hodoodo Cat#: H562103
Name: WNK-IN-11
CAS#: 2123489-30-3
Chemical Formula: C21H21Cl2N5OS
Exact Mass: 461.08
Molecular Weight: 462.390
Elemental Analysis: C, 54.55; H, 4.58; Cl, 15.33; N, 15.15; O, 3.46; S, 6.93
Synonym: WNK-IN-11; WNK IN 11; WNKIN11; WNK inhibitor 11; WNK inhibitor-11;
IUPAC/Chemical Name: (5-Chloro-2-(2-(methylamino)thiazol-4-yl)pyridin-4-yl)(4-(4-chlorobenzyl)piperazin-1-yl)methanone
InChi Key: MVXAYIXYYOVALX-UHFFFAOYSA-N
InChi Code: InChI=1S/C21H21Cl2N5OS/c1-24-21-26-19(13-30-21)18-10-16(17(23)11-25-18)20(29)28-8-6-27(7-9-28)12-14-2-4-15(22)5-3-14/h2-5,10-11,13H,6-9,12H2,1H3,(H,24,26)
SMILES Code: O=C(C1=CC(C2=CSC(NC)=N2)=NC=C1Cl)N3CCN(CC4=CC=C(Cl)C=C4)CC3
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 462.39 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Yamada K, Park HM, Rigel DF, DiPetrillo K, Whalen EJ, Anisowicz A, Beil M, Berstler J, Brocklehurst CE, Burdick DA, Caplan SL, Capparelli MP, Chen G, Chen W, Dale B, Deng L, Fu F, Hamamatsu N, Harasaki K, Herr T, Hoffmann P, Hu QY, Huang WJ, Idamakanti N, Imase H, Iwaki Y, Jain M, Jeyaseelan J, Kato M, Kaushik VK, Kohls D, Kunjathoor V, LaSala D, Lee J, Liu J, Luo Y, Ma F, Mo R, Mowbray S, Mogi M, Ossola F, Pandey P, Patel SJ, Raghavan S, Salem B, Shanado YH, Trakshel GM, Turner G, Wakai H, Wang C, Weldon S, Wielicki JB, Xie X, Xu L, Yagi YI, Yasoshima K, Yin J, Yowe D, Zhang JH, Zheng G, Monovich L. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016 Nov;12(11):896-898. doi: 10.1038/nchembio.2168. Epub 2016 Sep 5. PubMed PMID: 27595330.
2: Rosner MH, Perazella MA, Choi MJ. American Society of Nephrology Quiz and Questionnaire 2015: Electrolytes and Acid-Base Disorders. Clin J Am Soc Nephrol. 2016 Apr 7;11(4):735-44. doi: 10.2215/CJN.12801215. Epub 2016 Jan 29. PubMed PMID: 26825098; PubMed Central PMCID: PMC4822677.
3: Pasham V, Pathare G, Fajol A, Rexhepaj R, Michael D, Pakladok T, Alesutan I, Rotte A, Föller M, Lang F. OSR1-sensitive small intestinal Na+ transport. Am J Physiol Gastrointest Liver Physiol. 2012 Dec 1;303(11):G1212-9. doi: 10.1152/ajpgi.00367.2011. Epub 2012 Sep 27. PubMed PMID: 23019198.
4: Yang SS, Lo YF, Wu CC, Lin SW, Yeh CJ, Chu P, Sytwu HK, Uchida S, Sasaki S, Lin SH. SPAK-knockout mice manifest Gitelman syndrome and impaired vasoconstriction. J Am Soc Nephrol. 2010 Nov;21(11):1868-77. doi: 10.1681/ASN.2009121295. Epub 2010 Sep 2. PubMed PMID: 20813865; PubMed Central PMCID: PMC3014002.
5: Momeny M, Zakidizaji M, Ghasemi R, Dehpour AR, Rahimi-Balaei M, Abdolazimi Y, Ghavamzadeh A, Alimoghaddam K, Ghaffari SH. Arsenic trioxide induces apoptosis in NB-4, an acute promyelocytic leukemia cell line, through up-regulation of p73 via suppression of nuclear factor kappa B-mediated inhibition of p73 transcription and prevention of NF-kappaB-mediated induction of XIAP, cIAP2, BCL-XL and survivin. Med Oncol. 2010 Sep;27(3):833-42. doi: 10.1007/s12032-009-9294-9. Epub 2009 Sep 10. PubMed PMID: 19763917.
6: Yagi YI, Abe K, Ikebukuro K, Sode K. Kinetic mechanism and inhibitor characterization of WNK1 kinase. Biochemistry. 2009 Nov 3;48(43):10255-66. doi: 10.1021/bi900666n. PubMed PMID: 19739668.
7: Jun P, Hong C, Lal A, Wong JM, McDermott MW, Bollen AW, Plass C, Held WA, Smiraglia DJ, Costello JF. Epigenetic silencing of the kinase tumor suppressor WNK2 is tumor-type and tumor-grade specific. Neuro Oncol. 2009 Aug;11(4):414-22. doi: 10.1215/15228517-2008-096. Epub 2008 Nov 11. PubMed PMID: 19001526; PubMed Central PMCID: PMC2743221.
8: Cai H, Cebotaru V, Wang YH, Zhang XM, Cebotaru L, Guggino SE, Guggino WB. WNK4 kinase regulates surface expression of the human sodium chloride cotransporter in mammalian cells. Kidney Int. 2006 Jun;69(12):2162-70. Epub 2006 May 10. PubMed PMID: 16688122.
